GMP Deviations Lead WHO To Issue "Notice Of Concern" To Matrix Labs; May Suspend Prequalified Anti-AIDS Products
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The Indian drug industry received another blow to its reputation when the World Health Organization issued a "Notice of Concern" to Hyderabad-based Matrix Labs, which is now 90 percent owned by Mylan, the third-largest generic drug maker in the world
You may also be interested in...
Sun Feels The Heat As FDA Seizes Caraco Drugs; To Sign Consent Decree And Reset Guidance
MUMBAI - Days after U.S. FDA ordered seizure of 33 products from Caraco's Detroit-based manufacturing unit, its Indian parent Sun Pharma told investors that it will withdraw its earnings guidance and revise at a later date. Sun Pharma had set a guidance of 13-15 percent growth in 2009-10
As Ranbaxy Founders Exit, Daiichi Sankyo Assumes Complete Control; New Management Expects To Resolve U.S. FDA Issue
MUMBAI - Less than one year after acquiring a 64 percent equity stake in India's Ranbaxy for $4.6 billion, Japanese drug maker Daiichi Sankyo has taken complete control of the company's management after reaching an "amicable" agreement on the exit of Malvinder Singh, the grandson of Ranbaxy's founder, and two other directors: Sunil Godhwani and Balinder Dhillon
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).